| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jon C Cook | |
| James A Swenberg | |||
| David E Malarkey | |||
| Nancy G Doerrer | |||
| Samuel M Cohen | |||
| Abigail C Jacobs | |||
| James E Klaunig | |||
| Richard D Storer | |||
| Kay A Criswell | |||
| Vicki L Dellarco | |||
| Zbigniew W Wojcinski | |||
| David G Pegg | |||
| P433 | issue | 1 | |
| P304 | page(s) | 4-18 | |
| P577 | publication date | 2009-06-12 | |
| P1433 | published in | Toxicological Sciences | Q2446966 |
| P1476 | title | Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance | |
| P478 | volume | 111 |
| Q89185944 | A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)-The Case of Herbal Medicinal Products Containing St. John's Wort Extracts (SJW) |
| Q38689545 | A Balanced Risk-Benefit Analysis to Determine Human Risks Associated with Pyrrolizidine Alkaloids (PA)-The Case of Tea and Herbal Infusions. |
| Q89000215 | A non-retinoid antagonist of retinol-binding protein 4 rescues phenotype in a model of Stargardt disease without inhibiting the visual cycle |
| Q36530609 | A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis |
| Q37410536 | ARF suppresses hepatic vascular neoplasia in a carcinogen-exposed murine model. |
| Q37628343 | An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development |
| Q35086803 | An organizational approach for the assessment of DNA adduct data in risk assessment: case studies for aflatoxin B1, tamoxifen and vinyl chloride. |
| Q44195449 | Analysis of genomic mutation and immunohistochemistry of platelet-derived growth factor receptors in canine vascular tumours |
| Q47101799 | Beta Adrenergic Signaling: A Targetable Regulator of Angiosarcoma and Hemangiosarcoma |
| Q92751206 | Classification or non-classification of substances with positive tumor findings in animal studies: Guidance by the German MAK commission |
| Q36788733 | Constitutive Activation of mTORC1 in Endothelial Cells Leads to the Development and Progression of Lymphangiosarcoma through VEGF Autocrine Signaling |
| Q28742833 | Dog models of naturally occurring cancer |
| Q39470072 | Evaluation of direct and indirect effects of the PPARγ agonist troglitazone on mouse endothelial cell proliferation. |
| Q45125632 | Evaluation of expression profiles of hematopoietic stem cell, endothelial cell, and myeloid cell antigens in spontaneous and chemically induced hemangiosarcomas and hemangiomas in mice |
| Q36897201 | Evaluation of potential activity of luseogliflozin on vascular proliferation in the mesenteric lymph node with or without vascular tumors in Sprague-Dawley rats in a carcinogenicity study |
| Q47184255 | From the Cover: Fenretinide, Troglitazone, and Elmiron Add to Weight of Evidence Support for Hemangiosarcoma Mode-of-Action From Studies in Mice |
| Q33742809 | Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma |
| Q35067979 | Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas |
| Q50779030 | Human safety risk assessment of lymph node angiomas observed in 2-year carcinogenicity studies in rats. |
| Q38107000 | Hypothesis-based weight-of-evidence evaluation of the human carcinogenicity of toluene diisocyanate |
| Q42584249 | INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma |
| Q37672882 | Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. |
| Q90242418 | In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma |
| Q52647500 | Induction of hemangiosarcoma in mice after chronic treatment with S1P-modulator siponimod and its lack of relevance to rat and human. |
| Q42029702 | Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression |
| Q50213945 | Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite |
| Q42704053 | Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin |
| Q39174655 | Novel therapeutics for Stargardt disease |
| Q44409594 | Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives. |
| Q23919368 | Plastics and carcinogenesis: the example of vinyl chloride |
| Q92605942 | Primary Angiosarcoma of the Kidney: Case Report and Comprehensive Literature Review |
| Q58775480 | Primary angiosarcoma arising in an angiomyolipoma of the kidney: case report and literature review |
| Q30556645 | Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q92971607 | Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall |
| Q35603973 | Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings |
| Q35603965 | Successful drug development despite adverse preclinical findings part 2: examples |
| Q33706666 | Survival rates of homozygotic Tp53 knockout rats as a tool for preclinical assessment of cancer prevention and treatment |
| Q42723223 | Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies |
| Q37478093 | The role of hypoxia in 2-butoxyethanol-induced hemangiosarcoma. |
| Q48102317 | Unexpected Toxicology Findings in Rats Dosed With an Antihuman IL-13 Monoclonal Antibody |
Search more.